Resistance to standard chemotherapy was found to be associated with an EZH2-mediated histone modification H3K27me3 in the SCLC PDX model, and EZH2 inhibitors prevent SCLC from acquiring resistance to standard chemotherapy (Gardner et al., 2017). The gene discussed is EZH2; the disease is small cell lung carcinoma.